Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
Publication type: Journal Article
Publication date: 2003-08-01
scimago Q1
wos Q1
SJR: 1.304
CiteScore: 10.3
Impact factor: 4.2
ISSN: 14714892, 14714973
PubMed ID:
12901947
Drug Discovery
Pharmacology
Abstract
Targeted delivery of cytotoxic agents to tumours is believed to improve both their anti-tumour efficacy and their safety. Antibodies specific for tumour-associated antigens have been used to deliver cytotoxic agents to tumour cells. Calicheamicin is a potent cytotoxic agent that causes double-strand DNA breaks, resulting in cell death. When conjugated to monoclonal antibodies specific for tumour-associated antigens, calicheamicin exerts strong antigen-specific anti-tumour effects against human tumour xenografts in preclinical models. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Mylotarg), is a clinically validated therapeutic strategy for the treatment of human cancer.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
|
|
|
Blood
4 publications, 3.15%
|
|
|
Journal of Controlled Release
3 publications, 2.36%
|
|
|
European Journal of Medicinal Chemistry
3 publications, 2.36%
|
|
|
Bioconjugate Chemistry
3 publications, 2.36%
|
|
|
Journal of the American Chemical Society
3 publications, 2.36%
|
|
|
Natural Product Reports
3 publications, 2.36%
|
|
|
Biomedicines
2 publications, 1.57%
|
|
|
Cancer Immunology, Immunotherapy
2 publications, 1.57%
|
|
|
Leukemia
2 publications, 1.57%
|
|
|
Current Oncology Reports
2 publications, 1.57%
|
|
|
Advanced Drug Delivery Reviews
2 publications, 1.57%
|
|
|
Journal of Organic Chemistry
2 publications, 1.57%
|
|
|
Expert Opinion on Drug Delivery
2 publications, 1.57%
|
|
|
Journal of the National Cancer Institute
2 publications, 1.57%
|
|
|
Clinical Cancer Research
2 publications, 1.57%
|
|
|
Cancer Research
2 publications, 1.57%
|
|
|
Nature Cancer
1 publication, 0.79%
|
|
|
Biochemical Society Transactions
1 publication, 0.79%
|
|
|
Current Opinion in Oncology
1 publication, 0.79%
|
|
|
Cancer journal (Sudbury, Mass.)
1 publication, 0.79%
|
|
|
Antibodies
1 publication, 0.79%
|
|
|
Frontiers in Immunology
1 publication, 0.79%
|
|
|
Nature
1 publication, 0.79%
|
|
|
Drug Delivery and Translational Research
1 publication, 0.79%
|
|
|
Annals of Hematology
1 publication, 0.79%
|
|
|
Nature Reviews Drug Discovery
1 publication, 0.79%
|
|
|
Nature Biotechnology
1 publication, 0.79%
|
|
|
Cancer Chemotherapy and Pharmacology
1 publication, 0.79%
|
|
|
Nature Reviews Cancer
1 publication, 0.79%
|
|
|
1
2
3
4
|
Publishers
|
5
10
15
20
25
30
|
|
|
Elsevier
29 publications, 22.83%
|
|
|
Springer Nature
17 publications, 13.39%
|
|
|
Wiley
12 publications, 9.45%
|
|
|
American Chemical Society (ACS)
12 publications, 9.45%
|
|
|
Taylor & Francis
10 publications, 7.87%
|
|
|
Royal Society of Chemistry (RSC)
6 publications, 4.72%
|
|
|
American Association for Cancer Research (AACR)
4 publications, 3.15%
|
|
|
American Society of Hematology
4 publications, 3.15%
|
|
|
MDPI
3 publications, 2.36%
|
|
|
Oxford University Press
3 publications, 2.36%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 1.57%
|
|
|
Begell House
2 publications, 1.57%
|
|
|
Portland Press
1 publication, 0.79%
|
|
|
Frontiers Media S.A.
1 publication, 0.79%
|
|
|
Public Library of Science (PLoS)
1 publication, 0.79%
|
|
|
American Society of Clinical Oncology (ASCO)
1 publication, 0.79%
|
|
|
Hans Publishers
1 publication, 0.79%
|
|
|
Japanese Pharmacological Society
1 publication, 0.79%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.79%
|
|
|
Spandidos Publications
1 publication, 0.79%
|
|
|
IMR Press
1 publication, 0.79%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.79%
|
|
|
5
10
15
20
25
30
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
127
Total citations:
127
Citations from 2024:
18
(14.18%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Damle N. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin // Current Opinion in Pharmacology. 2003. Vol. 3. No. 4. pp. 386-390.
GOST all authors (up to 50)
Copy
Damle N. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin // Current Opinion in Pharmacology. 2003. Vol. 3. No. 4. pp. 386-390.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/S1471-4892(03)00083-3
UR - https://doi.org/10.1016/S1471-4892(03)00083-3
TI - Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
T2 - Current Opinion in Pharmacology
AU - Damle, N.
PY - 2003
DA - 2003/08/01
PB - Elsevier
SP - 386-390
IS - 4
VL - 3
PMID - 12901947
SN - 1471-4892
SN - 1471-4973
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2003_Damle,
author = {N. Damle},
title = {Antibody-targeted chemotherapy with immunoconjugates of calicheamicin},
journal = {Current Opinion in Pharmacology},
year = {2003},
volume = {3},
publisher = {Elsevier},
month = {aug},
url = {https://doi.org/10.1016/S1471-4892(03)00083-3},
number = {4},
pages = {386--390},
doi = {10.1016/S1471-4892(03)00083-3}
}
Cite this
MLA
Copy
Damle, N.. “Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.” Current Opinion in Pharmacology, vol. 3, no. 4, Aug. 2003, pp. 386-390. https://doi.org/10.1016/S1471-4892(03)00083-3.